Technology Innovation, People Centric
Endovastec™ is committed to provide trustworthy and universal access to state-of-the-art solutions of prolonging
and reshaping all lives, and to build a people centric enterprise ranking as a global leader of evolving and
emerging medical technologies through continuous innovation.
Products
Endovastec™ is committed to R&D, manufacturing, and sales of aortic and peripheral vascular interventional devices,
and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation,
drug coated PTA balloon catheters, and PTA balloon catheters etc.
Endovastec™ Reewarm™ PTX DCB PTA Catheter Receives Marketing Approval in Brazil
Brasilia, Brazil, 4 July 2022 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) today announced that it has received registration approval from the Brazilian Health Regulatory Agency (ANVISA) for its independently developed Reewarm™ paclitaxel (PTX) drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA) Catheter (“Reewarm™ PTX”).
05 Jul 2022
Endovastec™ Receives MDSAP Certificate for Brazil and Japan
Shanghai, China, 11 April 2022 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently announced that it has received a Medical Device Single Audit Program (MDSAP) certificate from the Technischer Überwachungs-Verein (TÜV SÜD), an international notified body, certifying Endovastec™’s compliance with both ISO13485:2016 standards and the regulatory requirements in Brazil, and Japan, which lays the groundwork and provides the momentum for the company's global development.
08 Apr 2022
Endovastec™ Announces Annual Results for 2021
Shanghai, China, 29 March 2022 - Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (hereafter referred to as "Endovastec™" or the “Group”) today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021 (hereafter referred to as the "Reporting Period"). In the reporting period, the Group recorded revenue of RMB 685 million, representing an increase of 45.59% as compared to the corresponding period of last year, with the net profit RMB 363 million, representing an increase of 45.15%. The net profit attributable to shareholders was RMB 316 million with an increase of 47.17%. The net profit excluding non-recurring gains and losses was RMB 289 million, an increase of 51.08%.
31 Mar 2022
Endovastec™ Castor™ Debuted at the First eCICE Conference in Brazil
São Paulo, Brazil, 30 October 2020 — The first virtual International Congress of Endovascular Surgery (eCongresso Internacional de Cirurgia Endovascular (eCICE)) kicked off as an online event from 7 – 8th September, 2020. As an influential conference in Latin America in the field of vascular surgery, the congress brought together vascular surgeons from around the world to showcase recent academic insights and developments in several cutting-edge application areas of endovascular treatment. Castor™ Branched Aortic Stent-Graft System (the “Castor™ Stent”), the world’s first stent system of the kind developed by Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), was launched on eCICE's live case demonstration.
19 Sept 2020
“Beyond the Road, Aortic Forum" International Aortic Forum Series Report
Shanghai, China – Recently, the 4th “Beyond the Road, Aortic Forum” was successfully held by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”, or “the Company”). There are 11 doctors from Argentina participated in this forum. Under the support from the top clinical centers on the field of aortic disease treatment in China, this forum aims to provide a long-term learning and communication platforms for overseas doctors in cardiac surgery and vascular surgery.
01 Sept 2019
Endovastec™ Joined ICARUS 2021 Symposium
Warsaw, Poland—Recently, Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), participated in the 2021 Interventional Endovascular Case Review European Symposium (ICARUS) at the invitation of the organizers.
05 Jun 2021